Hypertension in Pregnancy: A Decision Guide for Chronic vs. Gestational Hypertension

Gestational hypertension affects 6% to 8% of pregnancies and doubles lifetime cardiovascular disease risk, yet fewer than 20% of affected women receive any cardiac follow-up within five years of delivery. The 2022 CHAP trial established that treating mild chronic hypertension in pregnancy to a target below 140/90 mmHg reduces the composite of severe adverse outcomes by 18%, fundamentally changing the treatment threshold from prior guidelines that permitted pressures up to 160/110 mmHg before intervening.

The Fingerprint That Doesn’t Fade

She was told she had “a little high blood pressure in pregnancy,” gestational hypertension, and that it resolved. What she was not told: gestational hypertension still leaves a cardiovascular fingerprint.

I see her version of this story three times a week. A woman in her late forties presents with new-onset hypertension. Her internist orders the standard workup. I ask about pregnancy history. She mentions something about blood pressure “acting up” during her second pregnancy, twenty years ago. It went away. Nobody mentioned it again.

That silence costs lives.

Cardiovascular disease was the leading contributor to pregnancy-related deaths in the United States between 2018 and 2022, accounting for 869 deaths at a rate of 4.7 per 100,000 live births Chakhtoura et al. 2025. The maternal mortality rate increased 27.7% during this period. Among women over 40, the rate reached 138.5 per 100,000 births. Among Black women, 69.9 per 100,000.

These are not random tragedies. They are predictable cardiovascular events in women whose warning signs appeared decades earlier, during pregnancy, and were systematically ignored.

Pregnancy functions as a cardiovascular stress test. The heart increases output by 30% to 50%. Blood volume expands by 40%. Cardiac remodeling occurs. Vascular resistance drops, then rises. Women who develop hypertensive disorders during this stress test have revealed something about their underlying vascular biology. The question is whether anyone listens.

The Spectrum: Chronic, Gestational, and Preeclampsia

The terminology creates clinical confusion. Four distinct conditions exist on a continuum, each with different implications.

Chronic hypertension means blood pressure at or above 140/90 mmHg documented before pregnancy or before 20 weeks gestation. It complicates 1% to 2% of US pregnancies ACOG Practice Bulletin 203, 2019. These women enter pregnancy with established vascular disease.

Gestational hypertension means new-onset hypertension after 20 weeks gestation without proteinuria or signs of end-organ damage. Blood pressure must reach 140/90 mmHg on two occasions at least four hours apart. This affects 6% to 8% of pregnancies. 5 / Solid

Preeclampsia adds proteinuria (300mg or more in 24-hour urine, or protein/creatinine ratio above 0.3) or evidence of end-organ dysfunction: platelets below 100,000/μL, serum creatinine above 1.1 mg/dL, liver transaminases twice normal, pulmonary edema, or new-onset cerebral or visual disturbances ACOG Practice Bulletin 222, 2020.

Chronic hypertension with superimposed preeclampsia occurs when a woman with pre-existing hypertension develops new proteinuria or end-organ dysfunction after 20 weeks. This carries the highest risk.

The progression matters. Approximately 15% to 25% of women with gestational hypertension will develop preeclampsia ACOG 2020. The later gestational hypertension appears, the lower the conversion rate. Onset before 34 weeks signals higher risk.

The underlying mechanism is abnormal placentation. In normal pregnancy, trophoblast cells invade the spiral arteries of the uterine wall, transforming them from high-resistance vessels into low-resistance conduits. This transformation supports the massive increase in uteroplacental blood flow that the fetus requires.

In preeclampsia, this remodeling fails. Spiral arteries remain narrow. Placental hypoxia follows. The ischemic placenta releases antiangiogenic factors, primarily soluble fms-like tyrosine kinase-1 (sFlt-1), into the maternal circulation. sFlt-1 binds and inactivates vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). The resulting systemic endothelial dysfunction produces hypertension, proteinuria, and multi-organ damage Hauspurg et al. 2019. 5 / Solid

This is not a pregnancy problem that ends with delivery. This is a cardiovascular disease revealing itself under stress.

The CHAP Trial Changed Everything

For decades, obstetric guidelines permitted chronic hypertension in pregnancy to run at 160/110 mmHg before initiating treatment. The rationale: avoid hypotension that might compromise fetal perfusion. The 2015 CHIPS trial supported this permissive approach, showing no difference in pregnancy loss or neonatal intensive care admission between “tight” control (target diastolic 85 mmHg) and “less tight” control (target diastolic 100 mmHg) Magee et al. 2015.

Then came CHAP.

The Chronic Hypertension and Pregnancy (CHAP) trial enrolled 2,408 women with mild chronic hypertension, blood pressure between 140-159/90-104 mmHg, randomized to either active treatment targeting below 140/90 mmHg or standard care permitting higher thresholds Tita et al. 2022.

Active treatment reduced the primary composite outcome, severe hypertension, preeclampsia with severe features, preterm birth, placental abruption, or fetal/neonatal death, from 30.2% to 24.4%. The absolute risk reduction was 5.8%. The relative risk reduction was 18%. 5 / Solid

The number needed to treat was 15. Treat 15 women to prevent one serious adverse outcome.

importantly, active treatment did not increase small-for-gestational-age births. The longstanding fear of fetal growth restriction from aggressive blood pressure control proved unfounded.

CHAP used labetalol as the first-line agent, with nifedipine as the primary alternative. Both are safe. Both work. The threshold for action, not the specific medication, was the intervention.

This trial should have restructured prenatal care overnight. Chronic hypertension should now be treated to below 140/90 mmHg from the moment of diagnosis in pregnancy. Yet implementation lags. Old habits persist. The 160/110 threshold remains embedded in many clinical workflows.

Women don’t die from what they have. Women die from what they hold.

Safe Medications, Forbidden Medications

The medication list for pregnancy hypertension is short and well-established.

First-line agents:

• Labetalol: Combined alpha and beta blocker. Starting dose 100mg twice daily, maximum 2400mg daily in divided doses. Avoid in asthma.
• Nifedipine extended-release: Calcium channel blocker. Starting dose 30mg daily, maximum 120mg daily. Use the long-acting formulation only.
• Methyldopa: Central alpha agonist. Starting dose 250mg twice daily, maximum 2g daily. Sedation limits use.

Second-line agents:

• Hydralazine: Direct vasodilator. Primarily used for acute severe hypertension, not maintenance.
• Thiazide diuretics: Can be continued if used before pregnancy. Avoid initiating during pregnancy due to volume depletion concerns.

Absolutely contraindicated:

• ACE inhibitors (lisinopril, enalapril, ramipril): Cause fetal renal dysgenesis, oligohydramnios, and neonatal renal failure.
• ARBs (losartan, valsartan): Same fetotoxic profile as ACE inhibitors.
• Direct renin inhibitors (aliskiren): Fetal toxicity established in animal models.
• Atenolol: Associated with fetal growth restriction. Other beta-blockers are safer.
• Spironolactone: Antiandrogenic effects on male fetus.

The point is not that treating hypertension in pregnancy is complicated. The point is that it is straightforward when you know the list. Four drugs work. A handful are forbidden. Everything else falls between. 5 / Solid

For acute severe hypertension, defined as systolic 160 mmHg or higher or diastolic 110 mmHg or higher, ACOG recommends immediate treatment to prevent maternal stroke. IV labetalol (20mg initial bolus), IV hydralazine (5mg initial bolus), or oral immediate-release nifedipine (10mg) are all acceptable first-line options ACOG 2020. The goal is reduction to below 160/110 within 30 to 60 minutes, not normalization.

Stroke in pregnancy is a blood pressure emergency. It is also preventable.

The Long Shadow: Postpartum Cardiovascular Risk

The cardiovascular consequences of pregnancy hypertension extend decades beyond delivery.

A 2007 meta-analysis of 23 studies established the baseline: women with a history of preeclampsia have a 2.2-fold increased risk of future cardiovascular disease (HR 2.2, 95% CI 1.9-2.5), a 3.7-fold increased risk of chronic hypertension, and a 2.0-fold increased risk of ischemic heart disease Bellamy et al. 2007. 5 / Solid

Gestational hypertension without progression to preeclampsia still confers a 2.3-fold increased risk (RR 2.3, 95% CI 1.8-2.9) of developing chronic hypertension later in life Bellamy et al. 2007.

The risk is not hypothetical. A 2019 Circulation review confirmed that hypertensive disorders of pregnancy are now recognized as sex-specific cardiovascular risk factors, equivalent in magnitude to traditional risk factors like diabetes or smoking Hauspurg et al. 2019.

The American Heart Association incorporated pregnancy complications into cardiovascular risk assessment in 2011. Yet clinical translation remains poor. Most women leave obstetric care without any instruction about long-term cardiac surveillance. The handoff from obstetrician to primary care physician rarely includes cardiovascular counseling.

I call this the Peripartum Cardiovascular Information Gap. A woman’s most significant cardiac risk factor gets documented in her obstetric record, then disappears from her medical narrative.

The mechanism connecting pregnancy hypertension to future cardiovascular disease is not fully resolved, but two hypotheses dominate. The first is that pregnancy unmasks pre-existing vascular vulnerability. Women who develop preeclampsia may have had subclinical endothelial dysfunction before conception. Pregnancy’s hemodynamic stress revealed it.

The second is that preeclampsia itself causes lasting vascular damage. The systemic endothelial inflammation, the exposure to circulating antiangiogenic factors, the oxidative stress, these may create persistent arterial dysfunction that accelerates atherosclerosis.

Both hypotheses are probably true in different proportions for different women. What matters clinically is that the risk exists regardless of mechanism.

The Postpartum Year: The Window That Matters

The first year after delivery is the highest-risk period for cardiovascular events in women with pregnancy hypertension. It is also the year with the least structured cardiac care.

Current practice: Blood pressure is checked at the six-week postpartum visit. If normal, the woman is discharged from obstetric care. She may not see another physician for years.

Recommended practice: Women with any hypertensive disorder of pregnancy should have blood pressure documented at one to two weeks postpartum, repeated at three to six months, and annually thereafter for life. A thorough cardiovascular risk assessment should occur at 12 months postpartum, including lipid panel, fasting glucose or HbA1c, kidney function, and body mass index.

The International Society for the Study of Hypertension in Pregnancy (ISSHP) 2021 guidelines explicitly recommend that women with preeclampsia receive counseling about their increased cardiovascular risk and enter a structured surveillance program Brown et al. 2021. 5 / Solid

What does this look like in practice?

At the one-year mark, I order: fasting lipid panel (specifically LDL-C and ApoB if available), fasting glucose and HbA1c, thorough metabolic panel including creatinine and eGFR, and urine albumin-to-creatinine ratio. I calculate 10-year ASCVD risk using the pooled cohort equations, recognizing that these equations underestimate risk in young women, especially those with pregnancy complications.

If LDL-C exceeds 130 mg/dL, or if ApoB exceeds 100 mg/dL, we discuss statin therapy. If fasting glucose exceeds 100 mg/dL, we discuss metformin and lifestyle modification. If blood pressure exceeds 130/80 mmHg at any postpartum visit, we do not wait. We treat.

The goal is not to manage pregnancy as an isolated event. The goal is to intercept cardiovascular disease at its earliest detectable phase.

Future Pregnancy Planning: The Preconception Window

Women who have had preeclampsia or gestational hypertension face elevated risk in subsequent pregnancies. Preconception planning can modify that risk.

Low-dose aspirin (81-162mg daily) initiated between 12 and 16 weeks gestation reduces preeclampsia risk by approximately 17% in high-risk women ACOG 2020. High-risk criteria include prior preeclampsia, chronic hypertension, diabetes, kidney disease, autoimmune disease, or multiple gestation. 5 / Solid

Calcium supplementation (1,000-2,000mg daily) may reduce preeclampsia risk in women with low dietary calcium intake, particularly in populations where baseline intake is below 600mg daily.

Optimizing cardiovascular health before conception matters. Weight loss in obese women, achieving blood pressure control with pregnancy-safe medications, managing glucose in diabetics, these interventions reduce the stress that pregnancy will place on the vascular system.

The preconception visit should include: blood pressure measurement with documentation of pre-pregnancy baseline, metabolic screening (glucose, lipids, kidney function), medication review to identify and replace contraindicated drugs, and explicit counseling about pregnancy-specific cardiovascular risk based on prior history.

This is preventive cardiology applied to reproductive planning. The two fields have been artificially separated. They should not be.

The Clinical Framework: The Pregnancy Vascular Stress Test Model

Every pregnancy generates cardiovascular data. The question is whether that data enters the patient’s permanent health record in a way that future physicians can access and act upon.

I propose a documentation framework: the Pregnancy Vascular Stress Test Model.

Like a treadmill stress test, pregnancy places the cardiovascular system under defined hemodynamic load. Like a stress test, it produces a result: normal response, or abnormal response indicating underlying disease.

A woman who develops gestational hypertension has had an abnormal stress test. A woman who develops preeclampsia has had a markedly abnormal stress test. The result should be documented with the same permanence as any other diagnostic cardiac test.

The medical record should carry a problem list entry: “History of preeclampsia (2019), associated with 2.2-fold increased lifetime cardiovascular disease risk, requires annual cardiovascular surveillance.”

Every new physician who opens that record should see that entry. Every risk calculator should incorporate it. Every conversation about statins, blood pressure targets, or lifestyle modification should reference it.

This is not happening. We lose the signal in the noise of routine postpartum care.

The integration of obstetric cardiovascular history into lifetime preventive cardiology is one of the largest implementation gaps in women’s heart health. Closing it requires no new drugs, no new tests, no new technology. It requires only that we remember what happened and act accordingly.

Your Next Step

At your next appointment, whether with your obstetrician, primary care physician, or cardiologist, bring documentation of every pregnancy’s blood pressure history. If you had gestational hypertension, preeclampsia, or any blood pressure medication during pregnancy, state it explicitly and ask that it be added to your permanent problem list.

Then request these tests: fasting lipid panel including LDL-C (and ApoB if available), fasting glucose and HbA1c, thorough metabolic panel with kidney function, and urine albumin-to-creatinine ratio.

Ask your physician: “Given my pregnancy history, what is my 10-year cardiovascular risk, and what should we do about it?”

Print this article if needed. Hand it over. The conversation will follow.

Frequently Asked Questions

Does gestational hypertension go away after pregnancy?

Blood pressure typically returns to normal within 12 weeks of delivery in most women with gestational hypertension. This clinical resolution creates a false sense of security. The vascular dysfunction that allowed blood pressure to rise under the hemodynamic stress of pregnancy persists. A meta-analysis of 23 studies found that women with gestational hypertension have a 2.3-fold increased risk of developing chronic hypertension within the following decade. The condition resolves. The risk does not. Annual blood pressure monitoring should continue indefinitely. Any reading above 130/80 mmHg at a follow-up visit warrants discussion of treatment, not watchful waiting.

What blood pressure medications are safe during pregnancy?

Three medications have established safety profiles: labetalol, nifedipine extended-release, and methyldopa. Labetalol is typically first-line due to its efficacy and tolerability, starting at 100mg twice daily with a maximum of 2400mg daily. Nifedipine extended-release starts at 30mg daily, with a maximum of 120mg daily. Methyldopa remains an option but causes more sedation. ACE inhibitors, ARBs, and direct renin inhibitors are absolutely contraindicated throughout pregnancy due to severe fetal toxicity including renal dysgenesis. The CHAP trial demonstrated that treating chronic hypertension with these safe medications to a target below 140/90 mmHg reduces adverse pregnancy outcomes by 18% without increasing fetal growth restriction.

How do I know if I have preeclampsia versus gestational hypertension?

The distinction is clinical and laboratory-based. Gestational hypertension is defined as new-onset blood pressure at or above 140/90 mmHg occurring after 20 weeks of pregnancy, without proteinuria or evidence of end-organ damage. Preeclampsia requires the same blood pressure criteria plus either proteinuria (300mg or more in a 24-hour urine collection, or a protein-to-creatinine ratio above 0.3) or evidence of organ involvement. Organ involvement includes platelet count below 100,000 per microliter, serum creatinine above 1.1 mg/dL, liver transaminases elevated to twice normal, pulmonary edema, or new visual or cerebral symptoms. Approximately 15% to 25% of women with gestational hypertension will progress to preeclampsia, making serial monitoring essential.

What follow-up do I need after pregnancy hypertension?

Surveillance should be lifelong, with intensity matched to severity of the pregnancy complication. All women with any hypertensive disorder of pregnancy should have blood pressure checked at one to two weeks postpartum, again at six weeks, and annually thereafter. Women with preeclampsia or severe gestational hypertension should undergo thorough cardiovascular risk assessment at one year postpartum, including fasting lipid panel, fasting glucose or HbA1c, kidney function tests with eGFR, and urine albumin-to-creatinine ratio. Any blood pressure reading above 130/80 mmHg at follow-up warrants consideration of antihypertensive therapy. Document your pregnancy complications in your permanent medical record and inform every new physician.

Can I prevent preeclampsia in a future pregnancy?

Prevention is possible but not guaranteed. Low-dose aspirin (81-162mg daily) initiated between 12 and 16 weeks of gestation reduces preeclampsia risk by approximately 17% in women at high risk, which includes anyone with prior preeclampsia, chronic hypertension, diabetes, kidney disease, or autoimmune conditions. Calcium supplementation at 1,000 to 2,000mg daily may provide additional benefit in women with low dietary calcium intake. Optimizing health before conception, achieving a healthy weight, controlling blood pressure with pregnancy-safe medications, and managing glucose in diabetics, reduces the hemodynamic stress that pregnancy places on the vascular system. The preconception visit is an underutilized opportunity for cardiovascular risk reduction.